In particular, the sphingosine 1-phosphate receptor agonist fingolimod, approved for relapsing–remitting multiple sclerosis (RR-MS) therapy (Cohen et al., 2010; Kappos et al., 2010), emerged as a potential MCR1 agonist by a structure-based computational approach (Gesualdo et al., 2021). The gene discussed is S1PR1; the disease is myeloid sarcoma.